Weekly Investment Analysts’ Ratings Updates for Pfizer (PFE)

Pfizer (NYSE: PFE) has recently received a number of price target changes and ratings updates:

• 7/13/2026 – Pfizer had its price target lowered by BMO Capital Markets from $34.00 to $30.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Pfizer had its price target lowered by Guggenheim from $36.00 to $35.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Pfizer had its price target lowered by JPMorgan Chase & Co. from $30.00 to $28.00. They now have a “neutral” rating on the stock.
• 7/6/2026 – Pfizer was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $28.00 price target on the stock, down from $32.00.
• 7/6/2026 – Pfizer had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $27.00 price target on the stock.
• 7/4/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/23/2026 – Pfizer had its “outperform” rating reaffirmed by BMO Capital Markets.
• 6/21/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/13/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/9/2026 – Pfizer was upgraded by Royal Bank Of Canada from “underperform” to “sector perform”. They now have a $25.00 price target on the stock.
• 6/1/2026 – Pfizer had its “neutral” rating reaffirmed by Cantor Fitzgerald.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.